Figure 2.

Patient-Reported Medication Adherence (Ixazomib, Lenalidomide, Dexamethasone) Over Time (Cycles 1-5). Patients Had Self-Reported Their Monthly Medication Adherence Using a Choice of Provided Categories (Excellent, Very Good, Good, Fair, or Poor) to Answer the Question “Thinking About the Past 4 Weeks, Please Rate Your Ability to Take Your Oral Cancer Medication as Prescribed?” After Cycle 5, the Number of Evaluable Patients Was < 30%. The Maximum Number of Cycles Received at the Data Cutoff Was 25 (n = 1). Patient-Reported Monthly Medication Adherence Data for the Previous 4 Weeks Were Available Through to Cycle 24 (n = 1). †Percentages Were Calculated According to the Number of Patients Who Had Reported Medication Adherence in Each Cycle